merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>cheaper FDA‑approved vials offer a regulated, safer alternative, diminishing demand for lower‑priced but unregulated compounded drugs</answer>
<question_number>2</question_number>
<answer>it replicates the telehealth prescription‑and‑delivery model via LillyDirect, pulling patients directly to Lilly instead of third‑party telehealth compounders</answer>
<question_number>3</question_number>
<answer>reduced safety, quality and effectiveness oversight of compounded drugs</answer>
<question_number>4</question_number>
<answer>lower pricing entices self‑pay and compounded‑drug users to switch, helping Lilly recapture customers despite cutting into pen sales</answer>
<question_number>5</question_number>
<answer>compounding is allowed only while tirzepatide is on the FDA shortage list, so its removal would undercut compounding pharmacies and support Lilly’s legal actions</answer>
<question_number>6</question_number>
<answer>bypassing intermediaries to sell directly online with “transparent” lower prices</answer>
<question_number>7</question_number>
<answer>older Medicare patients may self‑fund the vials and face muscle‑loss‑related risks</answer>
<question_number>8</question_number>
<answer>positions Lilly’s vials as the safer, FDA‑approved choice, likely eroding confidence in compounded versions</answer>
<question_number>9</question_number>
<answer>FDA “in shortage” listing</answer>
<question_number>10</question_number>
<answer>undercutting compounding pharmacies through lower pricing</answer>
